The U.S. Food and Drug Administration said it approved Eli Lilly’s drug to treat a form of the most common type of lung cancer.

Sections:  business   
Topics:  health   
RELATED ARTICLES
BING NEWS:
  • Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
    Lilly raised its total-revenue outlook for 2024 by $2 billion to a range between $42.4 billion and $43.6 billion. The midpoint of management's expected-revenue range for this year is a whopping 51% ...
    05/3/2024 - 10:26 pm | View Link
  • Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
    Revenue hits $8.8 billion, up 26% Y/Y, driven by volume & higher prices. Strong demand for key drugs like Mounjaro & Verzenio. EPS beats at $2.58. FY24 guidance raised to $42.4 billion-$43.6 billion, ...
    04/30/2024 - 2:42 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News